Vaccine response after pneumococcal vaccination in allogeneic hematopoietic stem cell transplant recipients

Current guidelines for vaccination in allogeneic hematopoietic stem cell transplant (HCT) recipients recommend initiation of pneumococcal vaccination series three to six months post-HCT, with most data supporting initiation at six months due to a more robust immune response. This single-center, retr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2024-01, Vol.30 (1), p.15-18
Main Authors: Cheplowitz, Halle, Patel, Nimish, Kim, Alexander, Logan, Cathy, Law, Nancy, Koura, Divya, Haste, Nina, Medley, Katherine, Trinh, Julie, Sanders, Tyler, Taremi, Mahnaz, Saunders, Ila M
Format: Article
Language:English
Subjects:
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Immune response
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines
Retrospective Studies
Serotypes
Stem cell transplantation
Vaccination
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current guidelines for vaccination in allogeneic hematopoietic stem cell transplant (HCT) recipients recommend initiation of pneumococcal vaccination series three to six months post-HCT, with most data supporting initiation at six months due to a more robust immune response. This single-center, retrospective, observational chart review aimed to evaluate the impact of initiating the pneumococcal vaccine series at three months post-HCT compared to six months post-HCT. The primary endpoints were defined as a percentage of patients with a serologic response of >1 and >1.3 µg/mL for over 50% of the defined serotypes. Outcomes showed no difference in immunologic response between the two groups.
ISSN:1078-1552
1477-092X
DOI:10.1177/10781552231165733